CVS Met Earnings Growth Target, Ready for Future, CEO Lynch Says
- Shares dip as analysts question conservative guidance for 2021
- Company says it administered 3 million Covid vaccines so far
A worker checks in a person to receive a dose of the Moderna Covid-19 vaccine at a CVS Pharmacy in New York, U.S., on Feb. 12.
Photographer: Gabriela Bhaskar/BloombergThis article is for subscribers only.
CVS Health Corp. met its commitment of annual single-digit earnings growth, Chief Executive Officer Karen Lynch said in an interview Tuesday as analysts debated the health-care company’s outlook for the future.
The pharmacy giant said in a statement Tuesday it would have adjusted earnings of between $7.39 and $7.55 per share for 2021, citing rising retail sales. That beat the $7.50 average estimate of analysts. The company also announced it has administered 3 million Covid-19 vaccines so far in about 40,000 long-term facilities, a key part of the U.S. campaign to beat the pandemic.